Preparation, Characterization and Stability of Four Solid Forms of Ibrutinib

化学工业与工程

Chemcial Industry and Engineering

2018, Vol. 35

Issue (3) :38-42 DOI: 10.13353/j.issn.1004.9533.20182002

Current Issue | Next Issue | Archive | Adv Search

<< | >>

Preparation, Characterization and Stability of Four Solid Forms of Ibrutinib

Xu Yue^1,2, Wu Shuping¹, Chen Zhenzhen¹, Zhai Jinghuan¹, Lu Jie¹

1. School of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China;
2. School of Chemical Engineering, University of Ulsan, Ulsan 44610, Korea

Abstract	Reference	Related Articles

Download: PDF (1549KB) HTML () Export: BibTeX or EndNote (RIS) Supporting Info

Abstract

In this work, four solid forms of ibrutinib (form A, form B, form C and pseudo-polymorph anisole solvate) were prepared. The solid forms were characterized by X-ray diffraction, infrared spectroscopy and thermal analysis, and the stable form was selected by suspension experiments. The results show that the chemical and physical properties of the four forms of ibrutinib have obvious differences. The stability relationship of anhydrous forms is:form A>form C>form B, and form A is the thermodynamic stable crystalline form.

	Service

	Email this article
	Add to my bookshelf
	Add to citation manager
	Email Alert
	RSS
	Articles by authors
	Xu Yue
	Wu Shuping
	Chen Zhenzhen
	Zhai Jinghuan
	Lu Jie

Keywords： ibrutinib； polymorph； characterization； stability

Received 2017-12-20;

About author:

Cite this article:

Xu Yue, Wu Shuping, Chen Zhenzhen, Zhai Jinghuan, Lu Jie.Preparation, Characterization and Stability of Four Solid Forms of Ibrutinib[J] Chemcial Industry and Engineering, 2018,V35(3): 38-42

[1] Hilfiker R. Polymorphism in the pharmaceutical industry[M]. Weinheim:Hilfiker, 2006
[2] 王哲清. 药物多晶型与有效性[J]. 中国医药工业杂志,2005,36(7):442-446 Wang Zheqing. Polymorphism and drug availability[J]. Chinese Journal of Pharmaceuticals, 2005, 36(7):442-446(in Chinese)
[3] 吴霞,易学文.药物多晶型对药效及其理化性质影响的研究[J].四川理工学院学报:自然科学版,2007,20(3):48-50 Wu Xia, Yi Xuewen. Research of drug polymorphism[J]. Journal of Sichuan University of Science & Engineering:Natural Science Edition, 2007, 20(3):48-50(in Chinese)
[4] Cameron F, Sanford M. Ibrutinib:First global approval[J]. Drugs, 2014, 74(2):263-271
[5] Smyth M, Goldman E, Wirth D D, et al. Crystalline forms of a Bruton's tyrosine kinase inhibitor:US, 13908949[P]. 2013-12-19
[6] 李金亮,杨勤刚,任华森,等.依鲁替尼新晶型及其制备方法:CN,201510808526.7[P]. 2016-02-03 Li Jinliang, Yang Qingang, Ren Huasen, et al. New crystalline forms and preparation method of ibrutinib:CN, 201510808526.7[P]. 2016-02-03(in Chinese)
[7] 罗真秀,张洽洪,陈勇.依鲁替尼新晶型及其制备方法:CN, 201510246220.7[P]. 2015-11-25 Luo Zhenxiu, Zhang Qiahong, Chen Yong. New crystalline forms and preparation method of ibrutinib:CN, 201510246220.7[P]. 2015-11-25(in Chinese)
[8] 孙霖.依鲁替尼晶型F及制备方法:CN, 201610114027.2[P]. 2016-06-08 Sun Lin. Crystalline form F and preparation method of ibrutinib:CN, 201610114027.2[P]. 2016-06-08(in Chinese)
[9] 孙霖.依鲁替尼晶型G及制备方法:CN, 201610114028.7[P]. 2016-06-08 Sun Lin. Crystalline form G and preparation method of ibrutinib:CN, 201610114028.7[P]. 2016-06-08(in Chinese)
[10] 陈敏华,张炎锋,杨朝惠,等.PCI-32765的晶型A及其制备方法:CN,201410542609.1[P]. 2015-02-04 Chen Minhua, Zhang Yanfeng, Yang Chaohui, et al. Crystalline form A and preparation method of PCI-32765:CN, 201410542609.1[P]. 2015-02-04(in Chinese)
[11] Barbas R, Martí F, Prohens R, et al. Polymorphism of norfloxacin:Evidence of the enantiotropic relationship between polymorphs A and B[J]. Crystal Growth & Design, 2006, 6(6):1463-1467